

ENSAYOS CLÍNICOS GLÁNDULAS SALIVARES ABIERTOS A RECLUTAMIENTO (Actualizado Agsoto 2025)
FUENTE de la INFORMACIOÓN OBTENIDA: Clinical Trials.gov; EU Clinical Trials Register; REEC (AEMPS)

EU-CT	NCT	STUDY-Code	TITLE	PHASE	INDICATION	STADE	DRUG	SITES	SPONSOR
2024-517419-62-00	6760819	22752	A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) (panSOHO)	Phase II	HER2 mutation, Advanced solid tumors. Included Cohort: Salivary gland cancer	Recruiting	BAY2927088	H. Vall d'Hebron ICO Hospitalet START-F. Jimenez Diaz CUN	Bayer